Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties
Oncology Pharma Inc. (OTC PINK:ONPH) is exploring collaborations to enhance its licensed intellectual properties and therapy delivery methods as part of its research efforts. The Company aims to leverage economies of scale to produce innovative therapies. Additionally, discussions with industry players are underway to facilitate this objective. Oncology Pharma plans to utilize a single Clinical Research Organization (CRO) to streamline development processes and reduce costs. However, the press release includes forward-looking statements highlighting risks like cash flow issues and potential dilution from financing.
- Exploring collaborations for intellectual property enhancement.
- Aiming to produce proprietary therapies to support expansion.
- Intention to use a single CRO to save time and costs.
- Current negative operating cash flows may strain financial resources.
- Potential dilution from future financing could affect shareholder value.
- Risks associated with licensing arrangements and business relationships.
SAN FRANCOSCO, CA / ACCESSWIRE / June 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the 'Company') has been continuing its research and work reviewing and implementing collaboration between its interests in therapy, delivery and trial experience amongst its licensed products. The Company is in the early stages of reviewing the work and exploring opportunities between the synergistic value of its licensed Intellectual Properties and applying its expertise towards advancing the licensed IP we have with NanoSmart, Sybleu, Regen Biopharma and Ribera Solutions. The Company believes that it can take advantage internally of economies of scale and new IP can be created through a combination of therapies and delivery mechanisms.
In addition to seeking ways to enhance value with its existing portfolio of assets, Oncology Pharma has begun discussions within its network to identify key players to implement its goals. Being able to produce its own intellectual properties would be a key building block in the Company's objective towards expansion.
Oncology Pharma will further be looking into potentially utilizing a single CRO (Clinical Research Organization), in conjunction with its expertise within the Company, which management believes will save time and expense in getting the IP through the next steps of its development.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
through simple, practical and economical approaches.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/651749/Oncology-Pharma-Inc-Eyes-Collaboration-with-Patent-Opportunities-Amongst-Its-Licensed-Intellectual-Properties
FAQ
What initiatives is Oncology Pharma (ONPH) pursuing for its intellectual properties?
How is Oncology Pharma (ONPH) planning to reduce costs in its development processes?
What are the financial risks mentioned in Oncology Pharma's (ONPH) press release?
What is Oncology Pharma's (ONPH) outlook for future collaborations?
What challenges might Oncology Pharma (ONPH) face in achieving its business objectives?
